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BACKGROUND: Human immunodeficiency virus and injection 
substance use have an influence on genes and gene expression. 
These effects could be beneficial or detrimental in defining disease 
outcomes. Adiponectin gene is key in modulating metabolic and 
immunoregulatory functions. Understanding the effects of human 
immunodeficiency virus and injection substance use on the gene in 
the context of antiretroviral therapy is important for predicting 
disease outcomes.  
METHODS: This cross-sectional genetic study determined 
polymorphisms in the promoter region of adiponectin gene. Two 
variants were analyzed: rs2241766 and rs266729. Polymorphisms 
were associated with clinical markers of disease outcome; 
underweight, immunosuppression and viral suppression. The 
variants were genotyped via random fragment length 
polymorphism.  
RESULTS: GC haplotype was associated with higher odds of 
having underweight (OR, 2.21; 95% CI, 1.83-4.60; P=0.008 vs. OR, 
2.30; 95% CI, 1.89-4.71; P=0.006) in antiretroviral treatment -
naive and experienced injection substance users and 
immunosuppression (OR, 1.90; 95% CI 1.67-3.98, P=0.041) in 
naive. Bonferroni correction revealed GC haplotype carriers only 
to have low body mass index in both naive (median, 14.8; IQR, 3.2 
kg/m2; P<0.002) and experienced (median, 15.2; IQR, 3.2 kg/m2; 
P<0.002) injection substance users.   Circulating total adiponectin 
levels were higher in naive (median, 19.5; IQR, 7.9 µg/ml) than -
experienced (median, 12.0; IQR, 4.4 µg/ml) injection substance 
users (P<0.0001). GC carriers presented with low serum 
adiponectin levels in both study groups. 
CONCLUSION: The study revealed haplotypes of adiponectin gene 
at loci rs2241766 and rs266729 that could determine disease 
outcomes in human immunodeficiency virus -1 antiretroviral 
treatment- naive and experienced injection substance users.  
KEYWORDS: ADIPOQ gene, Injection substance use, Haplotypes 
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Of an estimated 13 million people who inject illicit 
drugs in the world, 1.7 million are HIV infected 
(1).  In Africa, ~630,000 people are injection 
substance users (ISUs) of whom 13.6% are living 
with HIV (2). In Kenya, over 50,000 ISUs have 
been identified, and the number is on the increase 
predominantly in coastal, urban, peri-urban areas 
and cities (3). The prevalence of HIV infection in 
Kenyan ISUs is ~18.3%  with higher incidence of 
18.7% mainly at the coast linked to high rates of 
injection substance use (4).  
Adiponectin gene (ADIPOQ) encodes 
adiponectin (5), a key adipokine  regulating 
carbohydrate and fat metabolism, immune and 
inflammatory responses (6).  ADIPOQ gene is 
~15.8 kb spanning across three exons on 
chromosome 3q27 (7). ADIPOQ gene is highly 
expressed in adipocytes, and moderately in renal 
epithelial cells, macrophages and CD4+ T cells 
(8,9).  Genetic variations in the ADIPOQ gene 
promoter loci -676 to +41  notably  rs2241766, 
rs266729, rs17300539, rs16861210, rs6444175 and 
rs1501299 are the most extensively studied in 
relation to disease outcomes across populations 
(10).  The rs2241766 variants are associated with 
metabolic syndrome, obesity and hypertension 
(10,11), while rs2241766 and rs266729 genotypes 
and haplotypes correlate with BMI in diabetics 
(12). Moreover, rs266729 is associated with non-
alcoholic fatty liver disease in smokers (13), and 
onset of type-2 diabetes mellitus (14).  In HIV 
infection, rs266729 GG variant is associated with 
low CD4+ T cell counts among patients on 
antiretroviral treatment (ART) (15).  Also, a review 
of the two loci using ENCODE, haploreg, HapMap 
and regulome databases revealed rs2241766 to be a 
synonymous SNP with enhancer histone markers in 
blood while rs266729 as an intronic variant 
associated with ADIPOQ gene expression. 
It appears that ADIPOQ variants mediate 
disease outcomes by controlling gene expression. 
For instance, in vitro studies in recombinant 
adiponectin treated HEK293 cells deficient in 
metabolic activity showed increased expression of 
the ADIPOQ gene in skeletal muscles (16). 
Moreover, several in vivo studies also showed that 
polymorphisms in the ADIPOQ gene influence 
gene expression which translates into altered 
circulating adiponectin levels (17).  In addition, 
ADIPOQ TG haplotype at rs2241766 and rs266729 
loci, and at +45 and +276 loci were associated with 
low circulating adiponectin levels in insulin 
resistant Korean and Indian patients, respectively 
(18).  Altogether, these findings suggest that 
haplotypes are better predictors of circulating 
adiponectin levels and disease progression. 
Additionally, underweight, immunosuppression 
and viral suppression are key clinical markers of 
disease progression in both HIV-infected and non-
infected ISUs (19).  However, there is limited data 
on how ADIPOQ gene polymorphisms influence 
these markers of disease progression among HIV-1 
ISUs. We have previously shown that serum 
adiponectin levels are low in HIV-1 ART-naive 
ISUs from coastal Kenya (20). In addition, 
injection substance use leads to epigenetic 
modifications in gene expression and causes 
alterations in the DNA sequences (17). 
Furthermore, HIV infection promotes a repertoire 
of up-regulations and/or down-regulations of 
human gene expression (21). Consequently, HIV-1 
ISUs provide a unique population in which gene 
regulation can be studied. Therefore, we examined 
associations of ADIPOQ gene variants at 
rs2241766 and rs266729 loci with underweight, 
immunosuppression and viral suppression among 




Study site and population: This cross-sectional 
study was conducted among HIV-1 ART-naive and 
-experienced ISUs from Mombasa, a coastal city in 
Kenya.  Detailed description of the study site and 
population, clinical and adiponectin measurements 
are presented in our recent publications (22).  In the 
current study, the ISUs were stratified into ART-
naive and -experienced individuals. ART-naive 
ISUs were individuals testing positive for HIV-1, 
reporting having never used ART and having no 
AIDS defining illnesses.  ART-experienced were 
individuals testing positive for HIV-1, currently on 
ART and having no AIDS defining illnesses.  The 
clinical measures of underweight, 
immunosuppression and viral suppression were 
used in examining ADIPOQ gene regulation of 
HIV-1 infection in ISUs.  Underweight was defined 
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by BMI <18.5 kg/m2 (23). Although WHO 
classifies HIV infection into four immunologic 
stages based on CD4+ T cell count (24), 
immunosuppression was based on CD4+ T cell 
count <500 cells/µl.  Viral suppression was also 
defined as per the WHO using >1000 HIV RNA 
copies/ml (25). 
 
CD4 T cell enumeration: CD4+ T cell counts 
were determined in an automated fashion using the 
BD FACSCalibur flow cytometer (Becton-
Dickinson™, Franklin Lakes, USA). Briefly, 5.0 µl 
of EDTA blood samples were placed in a tube and 
RBC lysis buffer added. After 5 minutes 
incubation, the cells were washed and fluorescent-
tagged antibodies (anti-CD3, anti-CD4, and anti-
CD45) were added. The cells were incubated for 30 
minutes after which the samples were washed and 
the CD4+ T cells enumerated on the flow 
cytometer. 
HIV-1 viral load: HIV-1 viral loads were 
determined using the automated Abbott m2000 
System according to the manufacturer’s 
instructions (Abbott Molecular Inc., Illinois, USA). 
Briefly, RNA was extracted from 0.2 ml serum 
samples and reverse-transcribed into cDNA. The 
cDNA was amplified using HIV-1-specific and 
internal control primers. Fluorescence intensity of 
the HIV-1 probe was converted into viral loads by 
the analyzer. 
Serum adiponectin measurement: Total 
adiponectin concentrations were determined in 
serum using commercial ELISA reagents according 
to the manufacturer's protocols (R&D Systems, 
Minneapolis, MN, USA). 
 
SNP selection strategy: SNPs rs2241766 and 
rs266729 were selected based on >5% distribution 
of alleles in HapMap populations (26,27). Also, 
location/co-localization with putative transcription 
factor binding sites and reported association with 
adiponectin levels was used. Furthermore, other 
adiponectin related traits and their closeness in 
genomic proximity were considered. 
DNA extraction and genotyping: DNA was 
extracted from dry blood spot (Whatman plc) 
samples using QiaAmp™ DNA Mini Kit (Qiagen 
Inc., Valencia, USA) according to the 
manufacturer’s protocols. Genotyping was carried 
out by PCR-restriction fragment length 
polymorphism (RFLP). PCR of DNA segments, 
containing rs2241766 and rs266729, was 
performed using the following primers: rs2241766, 
forward primer 5'- 
GCAGCTCCTAGAAGTAGACTCTGCTG -3' and 
reverse primer 5'- GCAGGTCTG 
TGATGAAAGAGGCC -3'; rs266729, forward 
primer 5'- GGTGGACTTGACTTTACTGG -3', 
and reverse primer 5'- 
TAGAAGCAGCCTGGAGAA -3'. PCR was 
carried out in a final volume of 50 µL containing: 5 
µL 10X PCR buffer (KEMTAQ®), 4 µL MgCl2, 2 µ 
dNTP, 10 pmol of each primer, 0.5 µL Taq DNA 
polymerase, 32.5 µL ddH2O, and 4 µL genomic 
DNA. The cycling conditions for rs2241766 and 
rs266729 were 94°C for 2 minutes, 35 cycles of 
94°C for 15 seconds, 60°C for 30 seconds, and 
72°C for 30 seconds. This was followed by a final 
extension at 72°C for 10 minutes and a pause at 
4°C. The PCR products were separated on a 2% 
UltraPure™ agarose gel and visualized under UV 
light. PCR products were digested with 10 U/µL 
restriction enzymes (New England Biolabs, 
Ipswich, USA). SNPs rs2241766 (SmaI), and 
rs266729 (HhaI) were genotyped by PCR-RFLP. 
The digested products were separated on a 2% 
NuSieve® 3:1 agarose gel (NuSieve® GTG® 
Agarose). The digests on agarose gel were read and 
scored separately by two different trained 
technologists- in the case of disagreement a third 
trained research assistant was called in. Samples 
that did not amplify for both variants were removed 
during analysis.  
Data analysis: Statistical analysis was performed 
using Statistical Package for the Social Sciences 
(SPSS) version 24.0 (SPSS Inc, Chicago, USA) 
and GraphPad Prism version 6.0 (GraphPad, 
California, USA). Continuous data such as age, 
height, weight, BMI, CD4+ T cell counts, log10 
HIV-1 RNA copies and adiponectin levels were 
compared between ART-naive and -experienced 
ISUs using the Mann-Whitney U test.  Discrete 
data and categorical data were compared between 
the study groups using the Fisher’s exact tests. 
Hardy-Weinberg equilibrium was determined using 
the Online Encyclopedia for Genetic Epidemiology 
studies software at www.oege.org/software/hwe-
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mr-calc.shtml. Haplotype distribution was 
determined using the HPlus haplotype analysis 
software-http://cdsweb01.fhcrc.org/HPlus/ and 
Haploview-www.broadinstitute.org/haploview. 
Kruskal-Wallis test was used to determine across-
haplotype differences, and where significant, post-
hoc Mann-Whitney U tests with the Bonferroni 
correction were performed with cut-off set at 
P<0.002. Binary logistic regression analyses were 
used to determine the associations of haplotypes 
with underweight, immunosuppression and viral 
suppression. In these regression models, we 
controlled for age, gender, duration and frequency 
of drug injection in the ART-naive; and age, 
gender, duration and frequency of drug injection, 
and duration of ART use in the ART-experienced 
ISUs. All tests were two-tailed and P<0.05 was 
used for statistical inferences.  
Ethics approval and consent to participate: 
Ethical approval for this study was obtained from 
Kenyatta University Ethics Review Committee 
(Protocol: PKU019/116/2012) and Masinde Muliro 
University of Science and Technology Institutional 
Ethical Review Committee (Protocol: MMU/COR-
403012-V27).  Written informed consent was 
obtained from each participant before enrolment. 
All HIV-1 infected ART-naive study participants 
were referred for further treatment and care at the 




Demographic and clinical profiles of the study 
participants: The demographic and clinical 
characteristics of the study participants are 
summarized in Table 1. A total of 284 adults (males, 
n=118 and females, n=166) comprising of HIV-1 
infected ISUs (ART-naive, n=108 and ART-
experienced, n=176) were recruited into the study.  
Age (median, 30.7; IQR, 6.7 years vs. median, 30.2; 
IQR, 6.3 years; P=0.708), gender (females, 53.7% vs. 
males 61.4%) and body height (median, 1.7; IQR, 0.2 
meters vs. median, 1.6; IQR, 0.4 meters; P=0.197) 
were comparable between the ART-naive and -
experienced subjects, respectively.    
Median body weight was significantly lower in 
ART-experienced (median, 53.7; IQR, 7.1 kg) 
compared to ART-naive (median, 49.5; IQR, 4.7 kg) 
ISUs (P=0.007). Likewise, BMI was significantly 
lower in ART-experienced (median, 14.1; IQR, 2.2 
kg/m2) relative to ART-naive (median, 17.7; IQR, 1.5 
kg/m2) ISUs (P=0.021). Consistent with the lower 
BMI, the rate of underweight was higher in ART-
experienced (47.2%) than in the ART-naive (31.5%) 
ISUs (P=0.009).  HIV-1 RNA copies/ml were similar 
between ART-naive and -experienced ISUs (median; 
2.6; IQR, 2.3 log10 HIV-1 RNA copies/ml vs median; 
2.2; IQR, 2.1 log10 HIV-1 RNA copies/ml P=0.291) 
as were the rates of viral suppression (50.0% vs. 
60.2%; P=0.170), respectively.  CD4+ T cell counts 
were also similar between the study groups (ART-
naive; median, 482; IQR, 434 cells/µl; -experienced; 
median, 408; IQR, 407 cells/µl; P=0.321). 
Consequently, the rates of immunosuppression were 
also similar among the groups (ART-naive, 50.0% 
and -experienced, 56.3%; P=0.109).  
 
 
Table 1: Demographic and clinical profiles of the study participants 
Characteristic HIV-1[+] ART [-], n=108 HIV-1[+] ART [+], 
n=176 
P 
Age, yrs. 30.7(6.5) 30.2 (6.3) 0.708 
Male/Female, n (%)  50/58(46.3/53.7) 68/108(38.6/61.4) 0.126 
Height, m 1.7(0.2) 1.6(0.4) 0.197 
Weight, kg 53.7(7.1) 49.5(4.7) 0.007 
Log10HIV-1 RNA copies/ml 2.6(2.3) 2.2(2.1) 0.291 
  <1000 54(50.0) 106(60.2) 0.170 
  ≥1000 54(50.0) 70(39.8) 
BMI, kg/m2  17.7(1.5) 14.1(2.2) 0.021 
  <18.5 34(31.5) 83(47.2) 0.009 
  ≥18.5 74(68.5) 93(52.8) 
CD4+ T cells/µl 482(434) 408(407) 0.321 
   <500 54 (50.0) 99(56.3) 0.109 
   ≥500 54(50.0) 77(43.7) 
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Haplotype frequencies: Haplotype frequencies 
are shown in Figure 1A. The TC haplotype was 
the most prevalent, with about equal distribution 
in the ART-naive (38.9%) and experienced 
(39.2%) ISUs (P=0.418). While the GC 
haplotype frequency was higher in ART-
experienced (22.7%) compared to -naive 
(14.8%) ISUs (P=0.031), the TG haplotype 
carriage was higher in the ART-naive (31.5%) 
compared to -experienced (25.0%) ISUs 
(P=0.007).  GG haplotype distribution was 
similar in the study groups (naive, 14.8% vs. 
experienced, 13.1%; P=0.214), respectively.   
Haplotype frequency distribution was consistent 
with HWE in the -naive (χ2=0.52, P=0.471) and 





Figure 1: ADIPOQ haplotype distribution and relationship with underweight, immunosuppression and viral 
suppression in HIV-1 ART-naive and -experienced ISUs. (A) Open and closed bars represent frequency (%) of 
haplotypes in -naive and -experienced ISUs, respectively. (B) Haplotypes vs underweight among -naive. (C) 
Haplotypes vs underweight among -experienced. (D) Haplotypes vs immunosuppression among -naive. (E) 
Haplotypes vs immunosuppression among -experienced. (F) Haplotypes vs viral suppression among -naive. (G) 
Haplotypes vs viral suppression among -experienced. Values in bold are significant P-values at a cut-off of P<0.05.  
 
Haplotype distribution in HIV-1 clinical 
outcomes: Haplotype distribution in different 
HIV-1 clinical outcomes is shown in Table 2. 
TC haplotype was the reference haplotype. 
Relative to TC, GC haplotype carriage was 
higher in underweight ART-naive (68.8% vs 
31.2%; P=0.001) and -experienced (62.5% vs 
37.5%; P=0.002) ISUs. Likewise, most of the 
GC haplotype carriers were immunosuppressed 
in both -naive (62.5% vs 37.5%; P=0.002) and -
experienced (67.5% vs 32.5%; P=0.001) ISUs.  
GC haplotype carriers in both -naive (68.8% vs 
31.2%; P=0.001) and -experienced ISUs (62.5% 
vs 37.5%; P=0.002) were more virally 
suppressed. 
Table 2: Haplotype distribution in HIV-1 disease outcomes 
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Haplotype HIV-1[+] ART [-], n=108 HIV-1[+] ART [+], n=176 
BMI CD4 count Viral load BMI CD4 count Viral load 
 <18.5 ≥18.5 P <500 ≥500 P <1000 ≥1000 P <18.5 ≥18.5 P <500 ≥500 P <1000 ≥1000 P 
GC 11  5  0.001 10  6  0.002 11  5  0.001 25  15  0.002 27  13  0.001 25  15  0.002 
GG 8  8  0.998 9  7  0.178 7  9  0.441 11  22  0.763 22  11  0.763 23  10  0.132 
TC* 15  27  1.000 13  29  1.000 26  16  1.000 27  42  1.000 25  44  1.000 44  25  1.000 
TG 17  17  0.998 19 15  0.248 18 16 0.700 23  21  0.546 23  21  0.451 22  22  0.998 
 
Data are presented as numbers (n) of subjects. HIV-1, human immunodeficiency virus type-1. ART [-], anti-
retroviral treatment-naive. ART [+], anti-retroviral treatment-experienced. Data analysis was conducted using chi-
square tests. Values in bold are significant P-values. TC*-reference haplotype.  
 
Variation in HIV-1 clinical outcomes across 
haplotypes: Variation of clinical outcomes 
across haplotypes is shown in Table 3. BMI was 
significantly different across haplotypes in both 
naive (P<0.002) and experienced (P<0.002) 
ISUs. CD4 T cell counts only differed across 
haplotypes in naive (P<0.002) ISUs. Post-hoc 
correction analyses revealed that the GC 
(median, 14.8; IQR, 3.8 kg/m2 vs 15.2; IQR, 3.2 
kg/m2) haplotype carriers had significantly lower 
BMI compared to GG (median, 18.7; IQR, 1.4 
kg/m2 vs 18.3; IQR, 1.7 kg/m2), TC (median, 
18.7; IQR, 2.2 kg/m2 vs 18.5; IQR, 2.4 kg/m2) 
and TG (median, 20.1; IQR, 3.9 kg/m2 vs 18.8; 
IQR, 1.5 kg/m2) in both naive  and experienced 
ISUs (P<0.002), respectively. In contrast, the 
CD4 T cell counts were higher in TC (median, 
617; IQR, 314.5 cells/µl) haplotype carriers 
relative to GC (median, 461; IQR, 262.8 
cells/µl), GG (median, 442; IQR, 194 cells/µl) 
and TG (median, 464; IQR, 293.3 cells/µl) 
haplotype carriers in both naive ISUs only 
(P<0.002), respectively. 
 
Table 3: Variation of HIV-1 disease outcomes across haplotypes 
 
 




















































Viral suppression 2.5 (2.6) 4.9 
(3.6)a 








2.5 (2.7) 0.135 
Data are presented as medians (IQR). Bonferroni correction set at P<0.002. Significant comparisons between 
haplotypes are indicated as; aP<0.002 vs GG, TC and TG, bP<0.002 vs GC, GG and TG. 
 
 
Association of haplotypes with underweight: 
Previous studies showing that underweight is 
linked to low serum adiponectin levels and predicts 
wasting in HIV infection and substance use (28), 
led us to examine the relationship of ADIPOQ 
haplotypes and underweight. Associations of 
ADIPOQ haplotypes with underweight are shown 
in Figure 1B and C. The GC haplotype was 
associated with higher probability of having 
underweight in both ART-naive (OR, 2.21; 95% 
CI, 1.83-4.60; P=0.008) and -experienced (OR, 
2.30; 95% CI, 1.89-4.71; P=0.006) ISUs.    
 
Association of haplotypes and immune 
suppression: Since adiponectin promotes CD4+ T 
cell depletion  and decreased CD4+ T cell numbers 
predicts progression of HIV infection (29), we 
examined the association between ADIPOQ 
haplotypes and immunosuppression.  Associations 
of ADIPOQ haplotypes with immune suppression 
are shown in Figure 1D and E. This analysis 
revealed that GC (OR, 1.90; 95% CI 1.67-3.98, 
P=0.041) and GG (OR, 2.02; 95% CI 1.61-4.12, 
P=0.017) haplotypes were associated with a higher 
probability of having immunosuppression in ART-
naive and -experienced ISUs, respectively.  
 
Association of haplotypes with viral 
suppression: The viral load is associated with 
serum adiponectin and progression of HIV 
infection (30); hence, we examined whether 
ADIPOQ haplotypes were associated with viral 
suppression.  Associations of ADIPOQ haplotypes 
with viral suppression are shown in Figure 1F and 
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G. Analysis of the haplotypes revealed that GG 
(OR, 2.11; 95% CI 1.49-4.11, P=0.011) and TG 
(OR, 1.92; 95% CI 1.51-3.97, P=0.016) haplotypes 
were associated with a higher probability of having 
viral suppression in ART-experienced ISUs only. 
 
Circulating adiponectin levels vs. clinical 
markers: ELISA measurement of circulating total 
adiponectin levels in serum specimens showed that 
ART-experienced (median, 12.0; IQR, 4.4 µg/ml) 
ISUs had higher serum adiponectin in comparison 
to ART-naive (median, 19.5; IQR, 7.9 µg/ml; 
P<0.0001; Figure 2A) ISUs. Subsequent analyses 
by clinical status indicated that adiponectin levels 
were reduced in individuals presenting with 
underweight among ART-naive (median, 13.9; 
IQR, 3.7 µg/ml vs. median, 21.3; IQR, 9.2 µg/ml; 
P<0.007; Figure 2B) and -experienced (median, 
12.5; IQR, 2.2 µg/ml vs. median, 16.7; IQR, 4.2 
µg/ml; P=0.009; Figure 2C) ISUs.  Likewise, 
adiponectin levels were lower in individuals having 
immunosuppression in ART-naive (median, 19.5; 
IQR, 3.2 µg/ml vs. median, 26.9; IQR, 7.0 µg/ml; 
P=0.002; Figure 2D) and -experienced (median, 
11.9; IQR, 1.3 µg/ml vs. median, 13.2; IQR, 3.8 
µg/ml; P=0.006; Figure 2E) ISUs.   Moreover, 
individuals with viral suppression among ART-
naive (median, 19.9; IQR, 6.4 µg/ml vs. median, 
15.2; IQR, 4.7 µg/ml; P<0.001; Figure 2F) and -
experienced (median, 16.5; IQR, 5.1 µg/ml vs. 
median, 11.1; IQR, 2.5 µg/ml; P<0.031; Figure 
2G) had lower adiponectin levels. 
 
 
Figure 2: Serum adiponectin levels (µg/ml) in ART-naive and –experienced ISUs. (A) Overall serum 
adiponectin levels. Adiponectin levels by underweight, immunosuppression and viral suppression 
status in HIV-1 ISUs. Box plots showing adiponectin levels by underweight, immunosuppression and 
viral suppression status in -naive (B, D and F) and -experienced (C, E, and G).  
 
 
Association of haplotypes with circulating 
adiponectin levels: Since all the clinical markers 
of HIV infection were associated with decreased 
circulating adiponectin levels, we determined 
associations between ADIPOQ haplotypes and 
adiponectin levels (Figure 3). Carriers of the GC 
haplotype had lower adiponectin levels compared 
to non-carriers in both ART-naive (median, 17.3; 
IQR, 5.3 µg/ml versus median, 28.2; IQR, 9.2 
µg/ml; P=0.034; Figure 3A) and -experienced 
(median, 11.9; IQR, 5.7 µg/ml vs. median, 17.3; 
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IQR, 3.7 µg/ml; P=0.009; Figure 3B) individuals.  
In contrast, adiponectin levels were higher in TC 
carriers than in non-carriers in ART-naive (median, 
21.3; IQR, 2.9 µg/ml vs. median, 11.8; IQR 1.8 
µg/ml; P=0.002; Figure 3E) and -experienced 
(median, 12.7; IQR, 5.8 µg/ml vs. median, 8.4; 
IQR, 4.6 µg/ml; P=0.012; Figure 3F). 
 
 
Figure 3: Box plots showing serum adiponectin levels in GC, GG, TC and TG haplotype carriers 





This study focused on two variants of the ADIPOQ 
gene: rs2241766 and rs266729. Both variants occur 
in regions where transcription factors bind to the 
gene (11). We compared haplotype distribution 
between the two study groups. Four possible 
haplotypes were generated- GC, GG, TC, and TG. 
Rate of GC carriage was lower in the -naive 
compared to -experienced ISUs. In contrast, TG 
carriers were more in HIV-1 ART-naive ISUs 
compared with -experienced suggesting that 
ADIPOQ haplotypes could be influencing disease 
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outcomes in HIV-1 ISUs. Previous studies have 
reported ADIPOQ haplotypes modulating obesity 
and type 2 diabetes (31). There is limited data on 
ADIPOQ haplotype modulation of disease 
outcomes in infectious diseases including HIV-1. 
This study is the first one to describe ADIPOQ 
haplotypes in HIV-1 infected ISUs.  
      Consistent with our previous study (20), 
ART-naive ISUs had higher serum adiponectin 
levels suggesting that ART could directly or 
indirectly be causing lower levels of circulating 
adiponectin. Previous studies have associated ART 
use with low levels of serum adiponectin in HIV 
infected individuals. For instance, stavudine has 
been shown to lower serum adiponectin up to 3.8 
folds (32). In addition, a decrease in circulating 
adiponectin concentration has been reported in 
individuals on HAART (33). NRTIs have also been 
found to modulate lipodystrophy in HIV patients 
which is associated with altered circulating 
adiponectin levels (34). Evidence from genome 
wide association studies has revealed derangements 
that arise in genes involved in adipocyte 
differentiation and lipid metabolism on exposure to 
ARVs (35). Contrastingly, Morimoto et al., 
showed that hypoadiponectinemia exhibited by 
HIV-1 infected patients is not influenced by ART 
use (36). Taken together, these studies suggest a 
direct or an indirect effect of ART on the 
circulating levels of adiponectin.  
      Consistent with lower BMI, the GC haplotype 
was associated with higher odds of having 
underweight in both ART-naive and -experienced 
ISUs.  The GC haplotype carriers also had a higher 
chance of having immunosuppression in both the 
ART-naive and –experienced individuals.  These 
findings suggest that ADIPOQ haplotypes 
modulate HIV-1 infection and treatment outcomes.  
Indeed, ADIPOQ haplotypes have been previously 
associated with disease progression in several 
pathological conditions. For instance, the TG 
haplotype has been linked with disease outcomes 
for patients with insulin resistance, coronary heart 
disease and obesity (18). However, very few 
studies have investigated ADIPOQ haplotypes in 
the context of infectious diseases. Kato et al 
reported ADIPOQ haplotypes to be modulating 
serum adiponectin levels in HIV infected 
individuals (15), but no study has yet described 
ADIPOQ haplotypes in the context of HIV-1 ISUs. 
Our findings therefore imply that the GC haplotype 
could be driving deleterious disease outcomes in 
HIV-1 infected ISUs. Nonetheless, the association 
of ADIPOQ haplotypes with BMI in the current 
study should be interpreted with caution as age and 
gender of an individual correlate with BMI such 
that younger individuals and females are more 
likely to have a lower BMI (37).  
        Overall, our findings appear to predict that 
HIV-1, injection substance use, antiretroviral 
treatment and polymorphisms in the promoter of 
ADIPOQ gene modulate the circulating 
adiponectin levels. Furthermore, variations in the 
promoter region of the ADIPOQ gene may affect 
the affinity, avidity and magnitude for which the 
gene binds with its transcription factors both cis 
and trans upstream so as to initiate transcription. 
Therefore, this modulates transcription and 
subsequently translation altering the circulating 
adiponectin levels. This in turn affects disease 
outcomes in HIV-1 infected ART-naïve and -
experienced ISUs. 
      In conclusion, this study revealed associations 
between ADIPOQ gene variant haplotypes and 
clinical markers in HIV-1 ISUs. ADIPOQ 
polymorphisms can thus be used as surrogate 
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